Glenmark Pharmaceuticals today said it has discovered a new drug molecule which can treat blood and lymph cancer, besides inflammatory disorders.
The novel biological entity, (NBE) ‘GBR 401’, was discovered by the company’s Switzerland-based arm Glenmark Pharmaceuticals SA, the company said in a statement.